Kiniksa Pharmaceuticals International, plc

Good day, and thank you for standing by. Welcome to the Connexa Pharmaceuticals first quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require assistance during the conference, please press star 0. I would now like to hand the conference over to Rachel Frank, head of investor relations. Please go ahead.

Thank you, operator. Good morning, and thank you for joining Connexa's call to discuss our first quarter 2022 financial results and corporate update. A press release highlighting these results can be found on our website under the Investors and Media section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Mote, our Chief Commercial Officer, will provide an update on our ARCLIS commercial execution. Then Mark Ragosa, our Chief Financial Officer, will review our first quarter 2022 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session for which John Paolini, our Chief Medical Officer, and Eben Tesari, our Chief Operating Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements, except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. I'm really happy to review our first quarter 2022 results today. It's been a full year since the commercial launch of Arclist for recurrent pericarditis. We're really happy with the progress we've made so far and in bringing Arclist to patients in need. I'm delighted to report that the net revenue for Arclist for the first quarter of 2022 was $22.2 million. Ross will cover our commercial performance in more detail, and overall, we've been incredibly pleased with the growth in prescriber adoption, patient adherence, and payer coverage. We're obviously also highly encouraged by the steady commercial growth of Arculus to date, and we plan to fully maximize on this opportunity. In addition to the launch, we remain focused on helping even more patients and building the most value from across our portfolio of clinical stage programs, and these include Vixarilumab, KPL-404, and Mavrolimumab. Starting with Vixarilumab, we're currently enrolling and dosing in a randomized placebo-controlled Phase IIb dose-ranging study in Parego nodularis. We expect data from this study in the second half of this year. For KPL-404, which is our CD40 program, we're enrolling and dosing in a phase two study in rheumatoid arthritis. This is a disease where the dose response has been well characterized, and our 12-week study is designed to provide not only PK characterization, but also an early signal of efficacy with chronic administration in a well-described patient population. The trial will potentially stand primarily as a proof of concept and could enable optionality to evaluate a range of other autoimmune diseases. For MAVRI, we remain highly encouraged by its broad potential, which, as you recall, has been demonstrated by positive clinical data across multiple indications. We're currently evaluating its development in rare cardiovascular diseases where the GMCFF mechanism has been implicated. We also continue to be very active in our business development efforts, which are focused on opportunities that have synergies with our existing commercial infrastructure, as well as the other assets in our pipeline. In essence, we are making tremendous progress across our entire portfolio, and we believe well-positioned for growth. So with that, I'll turn it over to Ross to review our commercial performance in more detail.